Evolus (EOLS) Stock Forecast & Price Target

Evolus Inc reported a 3.7% year-over-year increase in total net revenue, reaching $69.4 million, driven by heightened demand for Jeuveau and the successful launch of the Evolysse dermal filler line. The company anticipates that Evolysse may contribute approximately $33 million, or 10-12% of its 2025 top-line guidance, reflecting strong initial demand in the self-pay aesthetic market. Additionally, a growing trend among younger consumers favoring aesthetic treatments bodes well for the company's potential market share increase, particularly in light of competitors' pricing strategies in the broader industry.

Evolus Inc's adjusted gross margin declined to 66.5% from 71.5% year-over-year, primarily driven by a greater proportion of international sales and lower introductory pricing aimed at increasing uptake. The company significantly revised its 2025 net revenue guidance down to $295-$305 million, reflecting a growth rate that has been halved compared to prior expectations, underscoring a challenging macroeconomic environment. Additionally, Jeuveau experienced its first year-over-year sales decline since launch, with a 13% quarter-over-quarter and 11% year-over-year drop to $59 million, indicating weakening consumer sentiment and overall softness in the U.S. aesthetic market.